The global injection pen market is anticipated to grow at a CAGR of 6.8% over the forecast period. The market is segmented on the basis of type and disorder type. Based on the disorder type, the market is segmented into diabetes, hormonal disorders, arthritis, and others. The diabetes segment of the market is estimated to witness significant growth in the market. The key aspects that drive the segmental growth of the injection pen market include the increased incidences of autoimmune disorders primarily diabetes and arthritis among the people across the globe.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/injection-pen-market
There has been an upsurge witnessed in the prevalence of diabetes across the globe. As per the WHO, diabetes prevalence has been increasing steadily over the past three decades. In 2019, the diabetic population was nearly 463 million which is expected to rise to 578 million by 2030 as per the IDF, which will further raise to 700 million by 2045. These numbers specify an increase in the prevalence of diabetes which will demand the proper treatment options including insulin. Thus, owing to the higher demand for safe insulin delivery devices, the segment is likely to witness an upsurge over the forecast period.
Market Coverage
- Market number available for – 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segment Covered- By Type and By Disorder Type
- Regions Covered- North America, Europe, Asia-Pacific, Rest of the World
- Competitive Landscape- Eli Lily & Co., F. Hoffmann-La Roche Ltd., Pfizer Inc., Becton, Dickinson & Co., Novo Nordisk A/S, Owen Mumford Ltd., and AstraZeneca Plc.
Key questions addressed by the report
- What is the market growth rate?
- Which segment/region dominates the market in the base year?
- Which segment/region will project the fastest growth in the market?
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Injection Pen Market – Segmentation
By Type
- Reusable
- Disposable
By Disorder Type
- Autoimmune Disorders
- Hormonal Disorders
- Orphan Diseases
- Others
A full report of Injection Pen Market is available at: https://www.omrglobal.com/industry-reports/injection-pen-market
Injection Pen Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- AstraZeneca Plc
- Bayer AG
- Becton, Dickinson & Co.
- Biocorp Production SA
- Copernicus
- Eli Lilly and Co.
- Hoffmann-La Roche Ltd.
- Gerresheimer AG
- Haselmeier GmbH
- Merck KGaA
- Mylan N.V.
- Novartis International AG
- Novo Nordisk A/S
- Owen Mumford Ltd.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
